Molecular evidence-based use of bone resorption-targeted therapy in prostate cancer patients at high risk for bone involvement.

摘要: BACKGROUND: To improve median survival of patients with prostate cancer that has metastasized to bone, we need better understand the early events metastatic process in skeleton and develop molecular tools capable detecting tumor cell dissemination into bones (micrometastasis stage). However, initial phase bone marrow is promptly followed by migration cells matrix, which a crucial step signals transformation micrometastasis macrometastasis stage clinically evident metastasis. The matrix requires activation local resorption. Such an event contributes hiding/ escaping from high immunologic surveillance cells. Within are establishing plethoric cell-cell interactions marrow-residing cells, ensuring their growth. Recently, RT-PCR detections marker transcripts, such as PSA PSMA mRNA performed RNA extracts peripheral blood nucleated biopsy, have enabled stratification localized being risk for extraprostatic disease involvement. Therefore, it conceivable bisphosphonate blockade resorption can inhibit during Consequently, assessment efficacy efficiency bisphosphonates arrest evolution lesions this particular clinical setting positive staging status (high involvement) warranted.